Alpha Cognition INC 10-Q quarterly reports

Alpha Cognition Inc. (ACOG) announced a significant increase in revenue for the second quarter of 2026, driven by strong product sales of ZUNVEYL, though the company continues to operate at a net loss.

Alpha Cognition Inc. achieved its first product and licensing revenue in Q3 2025, driven by the commercial launch of ZUNVEYL for Alzheimer's disease, despite increased operating expenses and a higher net loss.

Alpha Cognition Inc. reports its first product and licensing revenue following the commercial launch of ZUNVEYL for Alzheimer's, alongside increased net losses and a stated need for additional capital.

Alpha Cognition Inc. reports a net loss of $2.0 million for Q1 2025, with significant revenue growth driven by a new licensing agreement.

Alpha Cognition's Q3 2024 report details a net loss of $8.98 million, but also highlights the FDA approval of ZUNVEYL and a successful $50 million public offering.

Alpha Cognition Inc. reports a net loss of $7.1 million for the six months ended June 30, 2024, while highlighting FDA approval for ZUNVEYL and ongoing efforts to secure additional funding.